Subclinical Ventricular Dysfunction in Long-Term Acromegaly Assessed by Speckle-Tracking Echocardiography

Patricia Gadelha¹*, Eduardo C. L. Santos², Jose Castillo³ and Lucio Vilar¹

¹ Division of Endocrinology, Hospital das Clínicas, Pernambuco Federal University, Recife, Brazil, ² Division of Echocardiography, Hospital das Clínicas, Pernambuco Federal University, Recife, Brazil, ³ Division of Echocardiography, Escola de Ecocardiografia de Pernambuco, Recife, Brazil

Introduction: Symptomatic heart disease may be present in patients with advanced-stage acromegaly. However, earlier assessment of subclinical ventricular systolic dysfunction can be accomplished through speckle-tracking echocardiography (STE) for the study of myocardial strain. The few such studies in this population to date have produced conflicting results. This study was performed to evaluate the parameters of ventricular strain in patients with acromegaly with no cardiac symptoms.

Methods: In this prospective observational study, STE was performed in patients with active acromegaly with no detectable heart disease and in a control group to assess ventricular dysfunction through global longitudinal strain (GLS), radial strain, circumferential strain, and twist. The left ventricular (LV) ejection fraction, LV mass index, and relative wall thickness were also compared between the groups.

Results: Twenty-five patients with active acromegaly (median age, 49 years; median disease duration, 11 years) and 44 controls were included. LV hypertrophy was more prevalent in the acromegaly group (40% vs. 19%, p < 0.01). The LV ejection fraction was similar between the groups (65.2% ± 5.99% vs. 62.9% ± 7.41%). The mean GLS (−18.8 ± 2.49 vs. −19.7 ± 3.29, p = 0.24), circumferential strain (−16.7 ± 3.18 vs. −16.6 ± 3.42, p = 0.90), and twist (14.6 ± 5.02 vs. 15.1 ± 3.94, p = 0.60) were not significantly different between the groups.

Conclusion: Despite showing higher rates of LV hypertrophy, patients with long-term acromegaly had no impairment of ventricular contractility as assessed by strain echocardiography when compared with a control group.

Keywords: acromegaly, left ventricular strain, echocardiography, left ventricular dysfunction, speckle-tracking echocardiography

INTRODUCTION

Acromegaly is a rare disease characterized by growth hormone (GH) and insulin-like growth factor type 1 (IGF-1) hypersecretion, and it is usually caused by a GH-producing pituitary adenoma (1). New effective treatments for acromegaly that have been developed in the last several years have improved the survival of patients with acromegaly (2, 3). Nonetheless, cardiovascular disease is still...
the most prevalent comorbidity and an important cause of mortality in patients with acromegaly (4, 5), thus requiring early diagnosis and appropriate treatment.

Acromegaly can cause a typical cardiomyopathy characterized by concentric biventricular hypertrophy (mainly of the left ventricle) that is associated with impaired diastolic function, which can progress to systolic heart failure (5). However, most echocardiographic studies have shown that systolic function is preserved and that symptomatic heart failure is an uncommon and late complication (6, 7). Therefore, identifying patients with acromegaly who have increased cardiovascular risk is the main challenge in avoiding this late phase of acromegalic cardiomyopathy.

Standard two-dimensional echocardiography has traditionally been applied to analyze structural and functional heart abnormalities in patients with acromegaly. Recent studies have employed more modern techniques such as speckle-tracking echocardiography (STE), which has allowed for the assessment of myocardial deformation or strain. This is a well-validated, reproducible tool that offers a more sensitive study of myocardial contractility (8). Strain describes deformation of the myocardium that occurs during the cardiac cycle in the longitudinal, circumferential, and radial planes (9). STE can be used to evaluate the global longitudinal strain (GLS), which reflects left ventricular (LV) function and may help to identify subclinical LV systolic dysfunction. Additionally, STE can be used to study other components of ventricular contraction, such as radial strain, circumferential strain, and ventricular rotation (twist) (10). Twist is the result of counterclockwise rotation of the LV apex with simultaneous clockwise rotation of the base. Reductions in GLS portend worse cardiovascular outcomes (11), and evaluation of such reductions has been applied to the early detection of heart valve diseases, myocardial ischemia, hypertrophic cardiomyopathy, and cancer therapy-related cardiac dysfunction as well as in the preclinical detection of cardiac involvement in systemic diseases, adding important information regarding the cardiovascular prognosis (12, 13).

Only a few studies have examined the effects of active acromegaly on ventricular deformation parameters, and these studies have shown conflicting results (14, 15). In the present study, we analyzed whether patients who had long-term active acromegaly with no cardiovascular symptoms would exhibit impaired parameters of ventricular deformation (strain) compared with a matched control group according to the impaired parameters of ventricular deformation (strain) compared with a matched control group according to the inclusion criteria of this study. We hypothesized that such reductions would be evident in patients with active acromegaly.

Acromegaly was diagnosed based on typical clinical features associated with elevated serum IGF-1 levels for age and sex, lack of GH suppression to <1 ng/mL during an oral glucose tolerance test, and positive pituitary magnetic resonance imaging findings (16, 17). Acromegaly was considered uncontrolled if the serum IGF-1 level was higher (>1.2 times the upper limit of normal [ULN]) than a standard cut-off age-adjusted normal range (18). The presumed duration of acromegaly was assessed by comparing old photographs and conducting interviews. The inclusion criteria were an age of >18 years and the presence of acromegaly not cured by neurosurgery.

The control group comprised 44 age- and sex-matched healthy individuals. Patients with a history of coronary artery disease, heart failure, valvular heart disease, stroke, peripheral arterial disease, chronic renal failure, and pregnancy were excluded from both groups.

Our study was approved by the human research ethics committee of our institution and complied with the Declaration of Helsinki. All patients and healthy volunteers provided informed consent.

**Clinical and Biochemical Parameters**

Obesity was defined as a body mass index of ≥30 kg/m². Arterial hypertension was defined as a systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg or the treatment of previously diagnosed arterial hypertension (19).

Plasma glucose, glycosylated hemoglobin, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were measured in the morning after a 12-hour fasting period. Low-density lipoprotein cholesterol was calculated by the Friedewald formula. Diabetes mellitus was diagnosed according to the American Diabetes Association criteria (20).

Plasma GH and IGF-1 levels were measured with a chemiluminescence assay kit (IMMULITE 2000; Los Angeles, CA, USA). The IGF-1 level was expressed as how many times it was above the ULN.

**Standard Echocardiography**

All healthy volunteers and patients with acromegaly underwent a complete two-dimensional transthoracic echocardiographic study as recommended by the American Society of Echocardiography (21) using a phased-array ultrasound system (Vivid i; GE Healthcare, Chicago, IL, USA). All studies were performed by a single investigator (E.C.L.S.).

In all cases, the LV dimensions, volumes, and ejection fraction and the left atrial dimensions were measured, and complete two-dimensional Doppler and tissue Doppler studies were performed. Ventricular volumes were calculated using the apical four- and two-chamber views, and the LV ejection fraction was calculated using the biplane Simpson formula. The LV mass (LVM) was calculated using the linear method as recommended by the American Society of Echocardiography for cardiac chamber quantification by echocardiography in adults (21). The relative wall thickness (RWT) was calculated from the LV end-diastolic dimension and posterior wall thickness with the following formula: RWT = (2 × posterior wall thickness)/LV end-diastolic dimension. The LVM was indexed (LVMi) to the

**PATIENTS AND METHODS**

**Study Design and Patients**

The study group comprised consecutive patients with active acromegaly who were recruited from the Neuroendocrinology Clinic of Hospital das Clínicas, Universidade Federal de Pernambuco, Recife, Brazil from July 2019 to June 2021. This was a cross-sectional, single-center study.
body surface area to determine LV hypertrophy. LV hypertrophy was defined as an LVMi of >115 g/m² in men or >95 g/m² in women. An increase in the LVMi was classified as having concentric geometry (RWT > 0.42) or eccentric geometry (RWT ≤ 0.42). Concentric remodeling was diagnosed if the LVMi was normal but the RWT was >0.42 (21).

**Speckle-Tracking Echocardiography**

The images selected for strain analysis were stored digitally for later offline analysis using dedicated software (EchoPAC PC, workstation version 204; GE Healthcare) performed by another investigator (I.C.) who was blinded to the patients' clinical data.

LV GLS was assessed in the four-, two-, and three-chamber apical views using automated function imaging software (10). The quality of myocardial tracking was visually assessed with the possibility of manual adjustments. The LV walls were divided into six segments in each apical view, and the tracking quality and strain value were assessed for each LV segment. The mean global longitudinal peak systolic strain was calculated for each view. GLS was the average of the value that was obtained for three apical views. By convention, GLS is a negative percentage number, indicating fiber shortening or myocardial thinning. Greater degrees of deformation therefore translate to numerically lower strain values. To avoid any misunderstanding, current guidelines recommend presenting the numerical data or referring to the change in deformation; thus, a reduced absolute strain value reflects contractile dysfunction (10, 21–24).

Short-axis views of the left ventricle at the basal, mid, and apical levels are necessary to obtain circumferential and radial strain, whereas the basal and apical views are needed to measure twist. Radial strain draws positive curves, and circumferential strain draws negative curves. Twisting is generated by opposite rotation of the LV base and apex. Basal and apical LV rotation are expressed in degrees, and twist is the result of the difference between apical and basal rotation (22).

**Statistical Analysis**

Statistical analyses were performed using R software (25). For descriptive analyses, categorical variables are presented as percentage and frequency and numerical variables are presented as mean ± standard deviation when normally distributed; they are presented as median when non-normally distributed. The Shapiro–Wilk test was used to test normality. The chi-square test or Fisher’s exact test was used to compare categorical variables. Student’s t test or the Wilcoxon non-parametric was used to compare numerical variables. Correlations between numerical variables were analyzed using Pearson’s or Spearman’s correlation test according to their distributions. A p value of <0.05 was considered statistically significant.

**RESULTS**

**Clinical and Biochemical Characteristics of Study Population**

In total, 34 patients with acromegaly were enrolled in the study, and 9 were excluded (1 with prior acute myocardial infarction, 1 with mitral regurgitation, and 7 with cured acromegaly). The mean age of the 25 remaining patients with active acromegaly was 49.9 ± 13.2 years, and 64% of the patients were female. The mean IGF-1 level was 1.68 times (range, 1.04–2.54) the ULN. The median disease duration was 11 years (range, 9–18 years). In the acromegaly group (n = 25), 13 patients (52%) had arterial hypertension and 16 patients (64%) had diabetes mellitus. Twenty patients (80%) had a history of transsphenoidal surgery. To achieve postsurgical hormonal control, 18 patients (72%) were using somatostatin analogs as monotherapy or in combination with cabergoline. Among the remaining seven patients not using somatostatin analogs, five had a recent diagnosis of acromegaly and were awaiting surgery. Only seven patients (28%) had controlled disease, defined as an IGF-1 level of up to 1.2 times the ULN (18).

The control group comprised 44 patients [28 women (63%); mean age, 48.4 ± 8.03 years]. Among the 44 patients, 23 (52%) had hypertension and 11 (25%) had diabetes mellitus.

In the acromegaly group, 71% of patients with arterial hypertension were on ACE-I/ARB (angiotensin converting enzyme inhibitors or angiotensin receptors blockers) therapy, the same occurring in 67% of those in the control group. This difference was not statistically significant.

The main clinical and biochemical characteristics of both groups are presented in Table 1.

---

**TABLE 1 | Clinical and biochemical features of patients with acromegaly vs. control group.**

|                          | Acromegaly Group | Control Group | p   |
|--------------------------|------------------|---------------|-----|
|                          | n = 25           | n = 44        |     |
| Sex (female/male, n)     | 16 / 9           | 28 / 16       | 1   |
| Age (years)              | 49.9 ± 13.2      | 48.4 ± 8.03   | 0.605|
| Body mass index (kg/m²)  | 30.7             | 27.9          | 0.062|
| Diabetes mellitus (%)    | 16 (64%)         | 11 (25%)      | 0.003|
| Arterial hypertension (%)| 13 (52%)         | 23 (52%)      | 1   |
| Disease duration (years) | 11 (9–18)        | NA            |     |
| IGF-1 levels (ULN)       | 1.68 (1.04–2.54) | NA            |     |
| Controlled disease (%)   | 7 (28%)          | NA            |     |

Values are presented as the mean ± SD. ULN, upper limit of normal; NA, not applicable.
Standard Echocardiographic Evaluation of LV Function

The LV ejection fraction was normal and similar between the groups (65.16% ± 5.99% vs. 62.9% ± 7.41%, p=0.19). Patients in the acromegaly group showed larger systolic volumes (31.8 ± 4.78 vs. 28.2 ± 3.81 mL, p = 0.001) and diastolic volumes (49.1 ± 5.96 vs. 45.0 ± 4.45 mL, p = 0.002) than subjects in the control group. The mean LVMi was higher in the acromegaly group than control group (87.9 ± 27 vs. 69.3 ± 17.5, p = 0.001). Compared with the control group, the acromegaly group presented more LV hypertrophy: 10 patients (40%) had changes in LV morphology and 7 (28%) had LV hypertrophy, whereas in the control group, 82% presented with normal geometry and only 1 (2%) had LV hypertrophy (p = 0.013). The findings of conventional echocardiography are shown in Table 2.

LV Myocardial Strain Assessed by STE

The mean GLS values were not significantly different between the groups (−18.84 ± 2.49 vs. −19.7 ± 3.29, p = 0.244). No correlation was found between GLS and disease control (shown in Figure 1). Additionally, we did not find any statistical correlation between GLS values and disease duration or arterial hypertension in the acromegaly group (Table 3). The global circumferential strain and twist values were also similar between the two groups (−16.74 ± 3.18 vs. −16.6 ± 3.42, p = 0.909 and 14.55 ± 5.02 vs. 15.1 ± 3.94, p = 0.609, respectively). The global radial strain (GRS) values were lower in the acromegaly group than control group (36.88 ± 9.24 vs. 45.9 ± 14.2, p = 0.003). Measures of myocardial strain in both groups are summarized in Table 4.

### DISCUSSION

Cardiovascular disease is the most prevalent comorbidity in patients with acromegaly and has a direct relationship with the duration of the disease (26) and lack of hormonal control (5). However, progression to overt systolic dysfunction is uncommon, developing in <3% of patients (3).

**TABLE 2 |** Standard echocardiography parameters in patients with acromegaly vs. control group.

| Parameter                                | Acromegaly Group | Control Group | p     |
|------------------------------------------|------------------|---------------|-------|
| LVEF Simpson (%)                         | 65.2 ± 5.99      | 62.9 ± 7.41   | 0.195 |
| LVEDV (ml)                               | 49.1 ± 5.96      | 45 ± 4.45     | 0.002 |
| LVESV (ml)                               | 31.8 ± 4.78      | 28.2 ± 3.81   | 0.001 |
| LVMi (g/m²)                              | 87.9 ± 27        | 69.3 ± 17.5   | 0.001 |
| RWT                                      | 0.39 ± 0.08      | 0.38 ± 0.08   | 0.487 |
| Normal LV geometry (%)                   | 15 (60)          | 36 (81.82)    | 0.013 |
| LV concentric hypertrophy (%)            | 4 (16)           | 1 (2.27)      |       |
| LV eccentric hypertrophy (%)             | 3 (12)           | 0 (0)         |       |
| LV concentric remodeling (%)             | 3 (12)           | 7 (15.91)     |       |

LVEF, left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; LVESV, left ventricular end systolic volume; LVMi, left ventricular mass index; RWT, relative wall thickness.

Strain analysis is a modern, validated, and useful tool to detect subclinical systolic cardiac dysfunction in several clinical scenarios (12, 27–30). GLS has superior prognostic value compared with the traditional ejection fraction for predicting major adverse cardiac events (11). However, its use to provide earlier diagnosis of acromegalic cardiomyopathy has not been extensively studied to date. In the present study in which we compared a group of patients with long-term active acromegaly to control subjects, neither with cardiovascular symptoms, we found no significant differences in the various parameters of myocardial strain. To our knowledge, this is the first study to analyze all parameters of myocardial strain in this specific population.

We used STE to determine ventricular strain measurements in this study. We found no significant differences in GLS, circumferential strain, or ventricular twist when comparing patients with acromegaly and controls, even considering that the patients had an estimated disease duration of 11 years and that most patients (72%) had uncontrolled disease. We also found no significant difference in the mean LV GLS when comparing subgroups of patients with controlled and uncontrolled acromegaly.

![FIGURE 1](https://example.com/image1.png) | Correlation between GLS values and disease control.
We found a higher prevalence of diabetes mellitus in the acromegaly group than in the control group (64% vs. 25%). This may have been a confounding factor if the acromegaly group had exhibited compromised strain measurements because diabetes mellitus can lead to diabetic cardiomyopathy, which can decrease the GLS (9). However, despite the fact that the patients with acromegaly had this higher risk, we still did not find significantly lower GLS values in this group.

Our findings are consistent with those of Volscham et al. (14), who assessed myocardial strain values in 37 patients with active acromegaly compared with 48 controls and found no differences in GLS between the patients and controls. Likewise, they found no correlation between GLS and disease duration or arterial hypertension in the acromegaly group.

Intriguingly, we found a reduction in GRS in the acromegaly group (36.88 ± 9.24 vs. 45.9 ± 14.2, p = 0.003). This is the first study to date to show this result in patients with acromegaly. However, although the absolute values of the GRS differed statistically from each other, they were within the normal range in both groups (between 35% and 59%) (31). Additionally, it is known that among the parameters of ventricular deformation, the GRS has the greatest number of limitations (31). Indeed, it has greater variability than the GLS (32), and such variability may be the result of a smaller portion of myocardial tissue needed to calculate GRS. Thus, small variations in the determination of the regions of interest could be associated with large differences in the result of radial strain (31).

The results of our study suggest that patients with acromegaly have a low risk of developing systolic dysfunction, and these findings are in line with more recent studies that show a trend toward lower cardiac complications in these patients (3) as well as a reduction in mortality by cardiac causes in the last decade (33). This could be a consequence of the better treatment of acromegaly and its cardiovascular comorbidities over time (34) or the difference between the pathophysiology of acromegaly-associated heart disease, which does not directly impair the cardiomyocyte contractility when compared with other causes of heart failure (35).

In fact, in the largest multicenter study designed to study the profile of patients with acromegaly, Petrossians et al. (36) found that only 1.6% of patients had heart failure. They also noted that patients with cardiac hypertrophy and heart failure at diagnosis were significantly older at diagnosis than those without cardiovascular complications (36). Therefore, they stated that because patients with acromegaly are living longer, the presence of acromegaly could simply represent an additional risk factor to many other contributory risk factors related to aging (36).

One of the limitations of the current study is its small sample size; however, it should be borne in mind that acromegaly is a rare disease. Additionally, this was a cross-sectional study, and a long-term prospective study could allow for a more detailed analysis of the evolution of functional cardiac parameters. Another potential limitation is the heterogeneity of the acromegaly group, since we had patients with disease duration ranging from 9 to 18 years and IGF-1 levels ranging from 1.04 to 2.54 times the upper limit of normal range. Additionally, SRL therapy has already been proved to be efficient in reducing ventricular hypertrophy (37) and in improving systolic and diastolic function (38). As a matter of fact, some studies have shown greater benefit of SRL therapy in reversing cardiomyopathy, when compared to surgical treatment alone, suggesting a possible direct beneficial of SRL on cardiomyocytes (39).

In conclusion, despite showing higher rates of LV hypertrophy, patients with acromegaly had no impairment of

**TABLE 3** | Correlation between GLS values and disease duration or arterial hypertension in the acromegaly group.

| Variable                      | GLS < 18% n = 9 | GLS > 18% n = 16 | p    |
|-------------------------------|-----------------|-----------------|------|
| Disease duration (years)      |                 |                 |      |
| <5                            | 0 (0)           | 2 (12.50)       | 0.82 |
| 5-10                          | 2 (22.22)       | 4 (25)          |      |
| >10                           | 7 (77.78)       | 10 (62.5)       |      |
| Arterial Hypertension         |                 |                 |      |
| Yes                           | 4 (44.44)       | 9 (56.25)       | 0.69 |
| No                            | 5 (55.56)       | 7 (43.75)       |      |
| Controlled disease            |                 |                 |      |
| Yes                           | 1 (11.11)       | 6 (37.50)       | 0.36 |
| No                            | 8 (88.89)       | 10 (62.50)      |      |

GLS, global longitudinal strain.

**TABLE 4** | Measures of myocardial strain in patients with acromegaly vs. control group.

| Measure            | Acromegaly Group | Control Group | p    |
|--------------------|------------------|---------------|------|
| GLS                | -18.84 ± 2.49    | -19.7 ± 3.29  | 0.244|
| GCS                | -16.74 ± 3.18    | -16.6 ± 3.42  | 0.909|
| GRS                | 36.88 ± 9.24     | 45.9 ± 14.2   | 0.003|
| Twist              | 14.55 ± 5.02     | 15.1 ± 3.94   | 0.609|

GLS, global longitudinal strain; GCS, global circumferential strain; GRS, global radial strain.
ventricular contractility as assessed by STE-derived myocardial strain when compared with a control group.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Human Research Ethics Committee of Hospital das Clínicas, Universidade Federal de Pernambuco. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. *Nat Rev Dis Prim* (2019) 5(1):20. doi: 10.1038/s41572-019-0071-6
2. Melmed S, Bronstein MD, Chanson P, Klubanski A, Casanueva FF, Wess JAH, et al. A Consensus Statement on Acromegaly Therapeutic Outcomes. *Nat Rev Endocrinol* (2018) 14(9):552–61. doi: 10.1038/s41574-018-0058-5
3. Colao A, Grasso LFS, Di Somma C, Pivonello R, Acromegaly and Heart Failure. *Heart Fail Clin* (2019) 15(3):399–408. doi: 10.1016/j.hfc.2019.03.001
4. Colao A, Ferone D, Marrullo P, Lombardi G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. *Endocr Rev* (2004) 25(1):102–52. doi: 10.1210/er.2002-0022
5. Pivonello R, Auriemma RS, Grasso LFS, Cimolii C, Patalano R, et al. Complications of Acromegaly: Cardiovascular, Respiratory and Metabolic Comorbidities. *Pituitary* (2017) 20(1):46–62. doi: 10.1007/s11102-017-0797-7
6. Bjørn H, Espinosa C, Valdes-Socin H, Salenave S, Young J, Levasseur S, et al. Long Term Outcome of Patients With Acromegaly and Congestive Heart Failure. *J Clin Endocrinol Metab* (2004) 89(11):5308–13. doi: 10.1210/jc.2004-0821
7. Mosca S, Filardi PP, Trimarco B, Conte S, Colao A, Leosco D, et al. Cardiovascular Involvement in Patients Affected by Acromegaly: An Appraisal. *Int J Cardiol* (2012) 167(3):1712–8. doi: 10.1016/j.ijcard.2012.11.109
8. Geyer H, Caraciglio G, Abe H, Wilansky S, Carej S, Gentile F, et al. Assessment of Myocardial Mechanics Using Speckle Tracking Echocardiography: Fundamentals and Clinical Applications. *J Am Soc Echocardiogr* (2010) 23(4):351–69. doi: 10.1016/j.echo.2010.02.015
9. Potter E, Marwick TH. Assessment of Left Ventricular Function by Echocardiography the Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction. *JACC Cardiovasc Imaging* (2018) 11:260–74. doi: 10.1016/j.jcmg.2017.11.017
10. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging. *Eur Heart J Cardiovasc Imaging* (2015) 16(1):1–11. doi: 10.1093/ehjci/ejv184
11. Kalam K, Othail P, Marwick TH. Prognostic Implications of Global LV Dysfunction: A Systematic Review and Meta-Analysis of Global Longitudinal Strain and Ejection Fraction. *Heart* (2014) 100(21):1673–80. doi: 10.1136/heartjnl-2014-305538
12. Klaeboe LG, Edvardsen T. Echocardiographic Assessment of Left Ventricular Systolic Function. *Echocardiogr* (2019) 17(1):10–6. doi: 10.1002/jc.21574-018-0405-5
13. Collier P, Phelan D, Klein A, Fuster V. A Test in Context: Myocardial Strain Measured by Speckle-Tracking Echocardiography. *J Am Coll Cardiol* (2017) 69(8):1043–56. doi: 10.1016/j.jacc.2016.12.012
14. Volschan ICM, Kasuki L, Silva CMS, Alcantara ML, Saraiva RM, Xavier SS, et al. Two-Dimensional Speckle Tracking Echocardiography Demonstrates No Effect of Active Acromegaly on Left Ventricular Strain. *Pituitary* (2017) 20(3):349–57. doi: 10.1007/s11102-017-0795-9
15. Uzieblo-Życzkowska B, Jurék A, Witek P, Zielinski G, Gierlerak G, Krzesiński P. Left Heart Dysfunction in Acromegaly Revealed by Novel Echocardiographic Methods. *Front Endocrinol (Lausanne)* (2020) 1:418. doi: 10.3389/fendo.2020.001418
16. Katzenelson L, Laws ER, Melmed S, Molitch ME, Murad MH, Uts A, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* (2014) 99(11):3933–51. doi: 10.1210/jc.2014-2700
17. Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. *J Clin Endocrinol Metab* (2020) 105(4):E937–46. doi: 10.1210/clinemd/dg096
18. Giustina A, Barkhoudarian G, Beckers A, Ben-shlomo A, Biermasz N, Biller B, et al. Multidisciplinary Management of Acromegaly: A Consensus. *Rev Endocr Metab Disord* (2020) 21(4):667–78. doi: 10.1007/s11154-020-09588-z
19. Barroso WKS, Rodrigues CFS, Bortolotto LA, Mota-Gomes MA, Brandão AA, de Magalhães Feitosa AD, et al. Brazilian Guidelines of Hypertension – 2020. *Arq Bras Cardiol* (2021) 116(3):516–658. doi: 10.36660/abc.20201238
20. Care D, Suppl SS. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2019. *Diabetes Care* (2019) 42:S13–28. doi: 10.2337/dci19-5002
21. Lang RM, Badano LP, Mor-avi V, Afilalo J, Armstrong L, Ermade L, et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update From the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* (2015) 28(1):1–39.e14. doi: 10.1016/j.echo.2014.10.003
22. Cameli M, Mondillo S, Solari M, Righini FM, Contaldi C, et al. Echocardiographic Assessment of Left Ventricular Systolic Function: From Ejection Fraction to Torsion. *Heart Fail Rev* (2016) 21(1):77–94. doi: 10.1007/s10741-015-9521-8
23. Narang A, Addetta K. An Introduction to Left Ventricular Strain. *Curr Opin Cardiol* (2017) 33(3):455–63. doi: 10.1097/HCO.0000000000000556
24. Blessingher H, Binder T. Two Dimensional Speckle Tracking Echocardiography: Basic Principles. *Heart* (2010) 96(9):716–22. doi: 10.1136/heartjnl-2007-140002
25. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing (2021). Available at: https://www.R-project.org/
26. Colao A, Pivonello R, Grasso LFS, Auriemma RS, Galdiero M, Savastano S, et al. Determinants of Cardiac Disease in Newly Diagnosed Patients With Acromegaly: Results of a 10 Year Survey Study. *Eur J Endocrinol* (2011) 165(3):713–21. doi: 10.1530/EJE-11-0408
27. Gadelha et al. Subclinical Ventricular Dysfunction in Acromegaly.
29. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert Consensus for Multimodality Imaging Evaluation of Adult Patients During and After Cancer Therapy: A Report From the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* (2014) 15(10):1063–93. doi: 10.1093/ehjci/jeu192
30. Dulgheru R, Pibarot P, Sengupta PP, Pierard LA, Rosenhek R, Magne J, et al. Multimodality Imaging Strategies for the Assessment of Aortic Stenosis: Viewpoint of the Heart Valve Clinic International Database (HAVEC) Group. *Circ Cardiovasc Imaging* (2016) 9(2):e004352. doi: 10.1161/CIRCIMAGING.115.004352
31. Yingchoncharoen T, Agarwal S, Popović ZB, Marwick TH. Normal Ranges of Left Ventricular Strain: A Meta-Analysis. *J Am Soc Echocardiogr* (2013) 26(2):185–91. doi: 10.1016/j.echo.2012.10.008
32. Oxborough D, George K, Birch KM. Intraobserver Reliability of Two-Dimensional Ultrasound Derived Strain Imaging in the Assessment of the Left Ventricle, Right Ventricle, and Left Atrium of Healthy Human Hearts. *Echocardiography* (2012) 29(7):793–802. doi: 10.1111/j.1540-8175.2012.01698.x
33. Ritvonen E, Löyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, et al. Mortality in Acromegaly: A 20-Year Follow-Up Study. *Endocr Relat Cancer* (2016) 23(6):1–30. doi: 10.1530/ERC-16-0106
34. Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, et al. French Acromegaly Registry Group. Changes in the Management and Comorbidities of Acromegaly Over Three Decades: The French Acromegaly Registry. *Eur J Endocrinol* (2017) 176(5):645–55. doi: 10.1530/EJE-16-1064
35. Saccà L, Napoli R, Cittadini A. Growth Hormone, Acromegaly, and Heart Failure: An Intricate Triangulation. *Clin Endocrinol (Oxf)* (2003) 59(6):660–71. doi: 10.1046/j.1365-2265.2003.01780.x
36. Petrossians P, Daly AF, Natchev E, Maione L, Blijdorp K. Acromegaly at Diagnosis in 3173 Patients From the Liège Acromegaly Survey (LAS) Database. *Endocr Relat Cancer* (2017) 24(10):505–18. doi: 10.1530/ERC-17-0253
37. Goldberg MD, Vadera N, Yandrapalli S, Frishman WH. Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options. *Cardiol Rev* (2018) 26(6):307–11. doi: 10.1097/CRD.0000000000000215
38. Colao A, Marrullo P, Cuocolo A, Spinelli L, Pironello R, Ronaduce D, et al. Reversal of Acromegalic Cardiomyopathy in Young But Not in Middle-Aged Patients After 12 Months of Treatment With the Depot Long-Acting Somatostatin Analogue Octreotide. *Clin Endocrinol (Oxf)* (2003) 58(2):169–76. doi: 10.1046/j.1365-2265.2003.01689.x
39. Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, et al. Octreotide LAR vs. Surgery in Newly Diagnosed Patients With Acromegaly: A Randomized, Open-Label, Multicentre Study. *Clin Endocrinol (Oxf)* (2009) 70(5):757–68. doi: 10.1111/j.1365-2265.2008.03441.x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Gadelha, Santos, Castillo and Vilar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.